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with Phenylketonuria: a rare association?
Laura Lucaccioni1,3, Bernd C Schwahn2, Malcolm Donaldson3 and Claudio Giacomozzi3,4*Abstract
Background: Central precocious puberty (CPP) and phenylketonuria (PKU) are two rare conditions, the latter being
the rarer. To date, only one case featuring both these conditions has been reported, and hyperphenylalaninemia
was assumed triggering CPP.
Case presentation: We present a 3.2 years old girl referred with a 12 months history of breast and pubic hair
development, and vaginal discharge. Hyperphenylalaninemia had been identified by newborn screening and PKU
subsequently confirmed by plasma amino acid and genetic analysis. Early dietary control of plasma phenylalanine
had been excellent afterwards, resulting in phenylalanine concentrations consistently within the recommended
range. Clinical scenario, hormonal assessment and imaging were in keeping with true idiopathic central precocious
puberty. Treatment with long lasting gonadotropin-releasing hormone analogue led to regression of secondary
sexual characteristics.
Conclusion: We describe for the first time CPP in a girl affected with PKU but with persistently well controlled
blood phenylalanine concentrations. This finding is in contrast to a previous report which suggested persistently
high phenylalaninemia levels as potential trigger for CPP in PKU patients. Our report, together with the lack of
evidence in published cohort studies of children with PKU, strongly suggests this rare association is coincidental
and independent of the presence of severe hyperphenylalaninemia.
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agonist treatmentBackground
True Central Precocious puberty (TCPP), also called
GnRH-dependent precocious puberty, can be defined
as true puberty, mediated by the hypothalamus, with
the onset of secondary sexual characteristics before the
age of eight in girls and nine in boys [1-4]. The estimated
incidence of TCPP is 1:5.000-10.000 throughout the world
[2] with a female:male ratio of between 3:1 and 23:1 [3]. It
is less common than, and should be differentiated from,
other forms of sexual precocity such as premature the-
larche and exaggerated adrenarche. Early activation of the
hypothalamic-pituitary-gonadal axis (HPGA) in TCPP is
mostly idiopathic, especially in girls [1-4]. However TCPP* Correspondence: dr.giacomozzi@gmail.com
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article, unless otherwise stated.may be secondarily related to brain tumors (hamartoma
especially), brain infections, congenital brain defects, cra-
nial irradiation, insults and injuries to the brain or spinal
cord (including cerebral palsy, hydrocephalus and brain
ischemia) [4]. Moreover TCPP has been widely described
in association with learning disability syndromes, includ-
ing Angelman, Kabuki make-up syndrome and other gen-
etic conditions in which mental retardation is a key
clinical feature [5-8]. Phenylketonuria (PKU) is an auto-
somal recessive disease caused by a deficient activity of
Phenylalanine Hydroxylase (PAH), the enzyme which me-
tabolizes Phenylalanine (Phe) to Tyrosine (Tyr). Deficiency
of PAH results in tyrosine deficiency, hyperphenylalanin-
emia (HP) and accumulation of Phe in other body fluids
[9]. If left untreated or not appropriately controlled, pa-
tients may develop mental retardation, microcephaly and
epilepsy due to the high sensitivity of the immature brain
to pathological Phe concentrations. Insufficiently treated
patients can also have behavioural problems and sometral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ledge only one girl affected by HP has been described in
the medical literature with associated TCPP [11]. In their
paper the authors highlight the poor control of serum
Phe level due to their patient’s inadequate adherence to
the low Phe diet and hypothesized that chronically ele-
vated Phe concentrations were the trigger of TCPP.
Since then, no other data supporting or rejecting this
conjecture have been reported. We present the case of
a three-year-old girl affected by severe PAH deficiency
who was diagnosed with TCPP, and have compared her
to the single case previously reported, pointing out dif-
ferences and similarities.
Case presentation
A girl was referred to our endocrinology outpatient
clinic at 3.2 years with a one year history of increasing
breast enlargement followed by the development of
pubic hair, body odour and brown vaginal discharge. She
had been born at 38 weeks gestation by caesarean sec-
tion due to maternal pre-eclampsia, birth weight 2.7 kg
(−0.72 SD). Her family history was negative for develop-
mental anomalies. Newborn screening revealed HP with
a Phe level of 435 μmol/L on day 5 and she was started
on dietary treatment from day 9 of life once severe iso-
lated hyperphenylalaninaemia had been confirmed with
plasma amino acid analysis (975 μmol/L). Bi-directional
sequence analysis of the PAH gene identified two hetero-
zygote mutations: p.Phe39Leu which is associated with
a variably severe phenotype, as well as a second well-
characterised null mutation, p.Pro281Leu. Her phenyl-
alanine tolerance remained around 200 mg per day
throughout the first 2.5 years of life. She showed nor-
mal neurodevelopment but for transitory mild speech
delay. From infancy to the time of referral the girl under-
went weekly Phe measurements with median (range)
values of 194 μmol/L (63–527) and thus almost exclu-
sively within the target range of 120-360 micromol/l for
children from 0 to 5 years of age in the UK (Figure 1).Figure 1 Patient serum Phe concentration from birth. The area within
in μmol/l.On examination in the endocrine clinic the girl was tall
in comparison to her parents’ height, 0.8 SDS according
to normal reference [12], while her mid parental height
(MPH) was −1.2 SDS, with a height corrected for MPH
of 2.0 SDS. Pubertal staging according to Tanner’s
method [13] was assessed at B4, P2, A1.
Results
Bone age was advanced by over one year at 4.62 years
using the TW2 (RUS) method [14] leading to a predicted
final height below the cut-off of −2.5 SDS. An LHRH
stimulation test was arranged and showed a pattern which
was diagnostic for TCPP (Table 1). Pelvic ultrasound scan
showed a bulky uterus of 4.75 cm length with a fundo-
cervical-ratio of 1.17 and endometrial thickness of 5.7 mm.
Ovaries were 1.70 and 0.78 ml in volume, both within the
normal volume range for age although large follicles were
evident. Brain and pituitary MRI showed a normal pituitary
gland with a mild convexity presentation compatible with
the HPGA activation, but no other organic causes for
TCPP were detected. Treatment with the GnRH agonist
(Triptorelin) was started at the dosage of 11.25 mg every
twelve weeks. After nine months, because of persistent
breast enlargement and increased height velocity, the inter-
val between injections was reduced to ten weeks. Subse-
quently the girl showed regression of breast development
and a decrease in height velocity. Now aged 4.6 years the
patient remains on treatment, showing reduced height vel-
ocity and regression of secondary sexual characteristics
(Table 1). Throughout treatment her dietary management
had been adjusted. Phenylalanine tolerance remains ele-
vated at around 350 mg per day on GnRH agonist treat-
ment and Phe concentrations have been maintained within
the target range with median (range) values of 194 μmol/L
(63–527).
Conclusions
Phenylketonuria was first described by Asbjørn Følling
in 1934 as one of the most common inherited metabolicdotted line represents the treatment target range. Phe concentration is
Table 1 Clinical and biochemical features in a girl with phenylketonuria presenting with sexual precocity aged 3 years
Age 3.2 yr 3.9 yr 4.2 yr 4.6 yr
Height, cm 98.8 (0.8) 107.5 (1.5) 109.7 (1.4) 111 (1.2)
Weight, Kg 16.1 (0.8) 18.54 (1.1) 18.76 (0.9) 19.44 (0.8)
BMI, Kg/m2 16.43 (0.4) 16.0 (0.2) 15.6 (0.0) 15.7 (0.1)
MPH, cm 156.0 (−1.2)
Ht corrected for MPH, SDS 2.0 2.7 2.6 2.4
Bone age, yr 4.62 - 5.37 -
Ht velocity, cm/y 14.3 (5.3) 10.6 (2.9) 7.1 (0.1) 4.3 (−2.2)
Pubertal status B4,P2,A1 B2,P2,A1 B1–2,P1, A1 B1–2,P1, A1
Basal/Peak LH, U/l 1.9/33.1
Basal/Peak FSH, U/l 2.4/6.5
Triptorelin dose 11.25 mg/12 weeks 11.25 mg/10 weeks 11.25 mg/10 weeks 11.25 mg/10 weeks
SDS is presented in brackets. Height velocity assessed according to Tanner et al. [13].
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North America is 1:10.000-15.000 live births [15]. It oc-
curs, however, more frequently in certain areas such as
Turkey (1:3.500-1:5.000), Ireland (1:4.500) or the West
of Scotland (1:7.500) [16]. Patients can be classified on
the basis of residual enzyme activity as judged by peak
blood Phe levels or, better, long-term phenylalanine
tolerance. Phe-restricted diets with amino acid and
micronutrient supplementation are highly effective in
preventing irreversible brain damage and allow for a
normal physical and cognitive development [10]. The
recommendations for acceptable safe blood Phe concen-
trations are to some extent age specific [17]. Our patient
has a severe enzyme deficiency with a low phenylalanine
tolerance, increasing the risk for neurocognitive anomal-
ies. Her parents achieved an excellent dietary control of
Phe concentrations with subsequent normal neurodeve-
lopment. To our knowledge, there is only one previous
case reported in the literature [11] describing TCPP in a
Turkish girl aged 7.5 years with severe PAH deficiency.
While most countries represented in the medical litera-
ture have universal neonatal screening programs in place
to avoid symptomatic PKU, classical PKU was diagnosed
late in this patient at 2.5 years of age, indicating that she
had been exposed to elevated Phe concentrations from
birth. Moreover, satisfactory Phe concentrations could
not be achieved in the girl because of poor adherence to
dietary recommendations. The authors assumed that per-
sistent poor dietary control could have prompted TCPP
due to a premature activation of the HPGA by a toxic
effect on the brain. Concerning this latter conjecture,
there are currently insufficient data in the literature as
to the incidence of TCPP in untreated or insufficiently
treated individuals with PAH deficiency. However, ex-
pert opinion corroborated by a poll of the metabolic
listserv “metab-l” suggests that this is an extremely rareoccurrence. Our patient is the first case where idiopathic
TCPP occurred under conditions of perfect dietary con-
trol. Since encountering TCPP in our patient we have
performed a literature search to identify studies that de-
scribe the growth pattern of patients with PKU, but none
of them focused on the timing of pubertal onset. Recent
studies of larger cohorts of individuals on PKU diets have
identified an increased prevalence of obesity and over-
weight towards adolescence in female subjects, with no
specific records about precocious or early pubertal pro-
gression [17,18]. Lack of evidence for different timing of
pubertal onset in PKU patients compared with the general
population corroborates our observation, and strongly
supports the notion of a co-incidental association between
PKU and TCPP. We can not entirely exclude, however,
that significant anomalies in the onset and tempo of pu-
berty in PKU patients might have been overlooked by pre-
vious population studies.
We conclude that TCPP is a rare coincidental event in
children with PKU and can occur independently by the
persistently high phenylalanine concentrations.
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